Abbott StarClose Opens Vascular Closure Options; U.S. Launch Set For 2005
This article was originally published in The Gray Sheet
Executive Summary
Abbott believes its StarClose vascular closure device will represent a competitive alternative to St. Jude's market leading AngioSeal upon U.S. approval in 2005
You may also be interested in...
St. Jude Daig Division Splits To Emphasize Vascular Closure, AF Devices
Newly appointed president of St. Jude Medical's cardiology division Paul Buckman will work to retain AngioSeal's number-one position in the U.S. vascular closure device market as newcomer Abbott Labs tries to gain ground
St. Jude Daig Division Splits To Emphasize Vascular Closure, AF Devices
Newly appointed president of St. Jude Medical's cardiology division Paul Buckman will work to retain AngioSeal's number-one position in the U.S. vascular closure device market as newcomer Abbott Labs tries to gain ground
Datascope Stock Rebounds With ProLumen Introduction; OTC Index Up 3%
Datascope's U.S. dialysis access market entry with the ProLumen peripheral thrombectomy device March 23 aided a 4.4% stock price gain for the month